In this article, we will discuss Trastuzumab (Dosage Overview). So, let’s get started.
Adjuvant Breast Cancer
Trastuzumab is indicated for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature) breast cancer
• as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
• with docetaxel and carboplatin
• as a single agent following multi-modality anthracycline based therapy.
Metastatic Breast Cancer
Trastuzumab is indicated:
• In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer
• As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease.
Metastatic Gastric Cancer
Trastuzumab is indicated in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction
adenocarcinoma, who have not received prior treatment for metastatic disease.
Recommended Doses and Schedules
Do not administer as an intravenous push or bolus. Do not mix Trastuzumab with other drugs.
Adjuvant Treatment, Breast Cancer
• Administer according to one of the following doses and schedules for a total of 52 weeks of Trastuzumab therapy:
• During and following paclitaxel, docetaxel, or docetaxel/carboplatin:
• Initial dose of 4 mg/kg as an intravenous infusion over 90 minutes then at 2 mg/kg as an intravenous infusion over 30 minutes weekly during chemotherapy for the first 12 weeks (paclitaxel or docetaxel) or 18 weeks (docetaxel/carboplatin).
• One week following the last weekly dose of Herceptin, administer Trastuzumab at 6 mg/kg as an intravenous infusion over 30-90 minutes every three weeks.
As a single agent within three weeks following completion of multi-modality, anthracycline-based chemotherapy regimens.
• Initial dose at 8 mg/kg as an intravenous infusion over 90 minutes
• Subsequent doses at 6 mg/kg as an intravenous infusion over 30-90 minutes every three weeks.
Metastatic Treatment, Breast Cancer
• Administer Trastuzumab, alone or in combination with paclitaxel, at an initial dose of 4 mg/kg as a 90 minute intravenous infusion followed by subsequent once weekly doses of 2 mg/kg as 30 minute intravenous infusions until disease progression.
Metastatic Gastric Cancer
• Administer Trastuzumab at an initial dose of 8 mg/kg as a 90 minute intravenous infusion followed by subsequent doses of 6 mg/kg as an intravenous infusion over 30-90 minutes every three weeks until disease progression.